Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells

详细信息    查看全文

• 作者：Paulina Grygielewicz ; Barbara Dymek ; Anna Bujak ; Pawel Gunerka…
• 关键词：Fibroblast growth factor receptor ; Epithelial–mesenchymal transition ; Drug resistance ; Fibroblast growth factor receptor inhibitor ; AZD4547 ; BGJ398
• 刊名：Gastric Cancer
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：19
• 期：1
• 页码：53-62
• 全文大小：2,735 KB
• 参考文献：1.Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16(2):139–49.PubMed CrossRef
  2.Kunii K, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 2008;68(7):2340–8.PubMed CrossRef
  3.Gru AA, Allred DC. FGFR1 amplification and the progression of non-invasive to invasive breast cancer. Breast Cancer Res. 2012;14(6):116.PubMed PubMedCentral CrossRef
  4.Billerey C, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158(6):1955–9.PubMed PubMedCentral CrossRef
  5.Pollock PM, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 2007;26(50):7158–62.PubMed PubMedCentral CrossRef
  6.Liao RG, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013;73(16):5195–205.PubMed PubMedCentral CrossRef
  7.Chesi M, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997;16(3):260–4.PubMed PubMedCentral CrossRef
  8.Singh D, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012;337(6099):1231–5.PubMed PubMedCentral CrossRef
  9.Dieci MV, et al. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013;3(3):264–79.PubMed CrossRef
  10.Mohammadi M, et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 1998;17(20):5896–904.PubMed PubMedCentral CrossRef
  11.Gavine PR, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012;72(8):2045–56.PubMed CrossRef
  12.Guagnano V, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011;54(20):7066–83.PubMed CrossRef
  13.Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMed CrossRef
  14.Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol. 2010;17(1):14–7.PubMed PubMedCentral CrossRef
  15.Zhao G, et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther. 2011;10(11):2200–10.PubMed CrossRef
  16.Guagnano V, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118–33.PubMed CrossRef
  17.Chell V, et al. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene. 2013;32(25):3059–70.PubMed CrossRef
  18.Byron SA, et al. The N550 K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia. 2013;15(8):975–88.PubMed PubMedCentral CrossRef
  19.Harbinski F, et al. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov. 2012;2(10):948–59.PubMed CrossRef
  20.Herrera-Abreu MT, et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 2013;3(9):1058–71.PubMed PubMedCentral CrossRef
  21.Bar-Am I, et al. Detection of amplified DNA sequences in human tumor cell lines by fluorescence in situ hybridization. Genes Chromosomes Cancer. 1992;4(4):314–20.PubMed CrossRef
  22.Xie L, et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res. 2013;19(9):2572–83.PubMed CrossRef
  23.Ku JL, Park JG. Biology of SNU cell lines. Cancer Res Treat. 2005;37(1):1–19.PubMed PubMedCentral CrossRef
  24.Rho JK, et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer. 2009;63(2):219–26.PubMed CrossRef
  25.Brunen D, et al. TGF-β: an emerging player in drug resistance. Cell Cycle. 2013;12(18):2960–8.PubMed PubMedCentral CrossRef
  26.Yauch RL, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res. 2005;11(24 Pt 1):8686–98.PubMed CrossRef
  27.Thomson S, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005;65(20):9455–62.PubMed CrossRef
  28.Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009;1796(2):75–90.PubMed
  29.Chaw SY, et al. Epithelial to mesenchymal transition (EMT) biomarkers – E-cadherin, beta-catenin, APC and vimentin – in oral squamous cell carcinogenesis and transformation. Oral Oncol. 2012;48(10):997–1006.PubMed CrossRef
  30.Kato N, et al. β-Catenin activation and epithelial-mesenchymal transition in the pathogenesis of pterygium. Invest Ophthalmol Vis Sci. 2007;48(4):1511–7.PubMed CrossRef
  31.Oft M, et al. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 1996;10(19):2462–77.PubMed CrossRef
  32.Gal A, et al. Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene. 2008;27(9):1218–30.PubMed CrossRef
  33.Kim YJ, et al. Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine. Anticancer Res. 2012;32(3):799–806.PubMed PubMedCentral
  34.Kim HR, et al. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol Oncol. 2013;7(6):1093–102.PubMed CrossRef
  35.van Malenstein H, et al. Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett. 2013;329(1):74–83.PubMed CrossRef
  36.Wang J et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2014. doi:10.​1038/​onc.​2014.​161 .
  37.Hanze J, et al. Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells. BMC Cancer. 2013;13:589.PubMed PubMedCentral CrossRef
  38.Nguyen PT, et al. The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1. Br J Cancer. 2013;109(8):2248–58.PubMed PubMedCentral CrossRef
  39.Warzecha CC, et al. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell. 2009;33(5):591–601.PubMed PubMedCentral CrossRef
  40.Shirakihara T, et al. TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J. 2011;30(4):783–95.PubMed PubMedCentral CrossRef
  41.De Medina SG, et al. Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas. Oncogene. 1999;18(41):5722–6.PubMed CrossRef
  42.Bai A, et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 2010;70(19):7630–9.PubMed CrossRef
  43.Huang S, et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell. 2012;151(5):937–50.PubMed PubMedCentral CrossRef
  44.Yao Z, et al. TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A. 2010;107(35):15535–40.PubMed PubMedCentral CrossRef
  45.Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 2012;11(10):790–811.PubMed PubMedCentral CrossRef
  46.Morrison CD, Parvani JG, Schiemann WP. The relevance of the TGF-β paradox to EMT-MET programs. Cancer Lett. 2013;341(1):30–40.PubMed CrossRef
  47.Suda K, et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol. 2011;6(7):1152–61.PubMed CrossRef
  
• 作者单位：Paulina Grygielewicz (1) (2)
  Barbara Dymek (1)
  Anna Bujak (1) (2)
  Pawel Gunerka (1) (3)
  Aleksandra Stanczak (1)
  Monika Lamparska-Przybysz (1)
  Maciej Wieczorek (1)
  Karolina Dzwonek (1) (4)
  Daria Zdzalik (1)
  
  1. Innovative Drugs R&D Department, Celon Pharma Inc., Mokra 41a, 05-092, Lomianki/Kielpin, Poland
  2. Postgraduate School of Molecular Medicine, Zwirki i Wigury 61, 02-091, Warsaw, Poland
  3. Department of Medical Biotechnology, Medical University of Lodz, Al. Kosciuszki 4, 90-419, Łodz, Poland
  4. Department of Immunology, Center for Biostructure Research, Medical University of Warsaw, Banacha 1a, F Building, 02-097, Warsaw, Poland
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Gastroenterology
  Surgical Oncology
  Pathology
  Radiotherapy
  
• 出版者：Springer Japan
• ISSN：1436-3305

文摘

Background Up to 10 % of primary gastric cancers are characterized by FGFR2 amplification, and fibroblast growth factor receptor (FGFR) inhibitors may represent therapeutic agents for patients with these malignancies. However, long-term benefits of the treatment might be limited owing to the occurrence of drug resistance.